Becton Dickinson (BDX) · Medical Devices
Becton Dickinson Q4 FY2026 earnings: summary, key numbers & outlook
Results filed 5 Nov 2026 · Quarter ended 29 Sep 2026
Slides (29 pages)Press release ↗Investor relations ↗
Summaries and transcripts are machine-generated and can contain errors.
In brief
BD signed a U.S. government manufacturing partnership with $19 billion of planned investment and Section 232 tariff relief, while launching new vascular and tissue-regeneration products as New BD.
BD finished its transformation into a four-segment MedTech company after spinning off its Biosciences and Diagnostic Solutions business into Waters in February. Growth was led by Advanced Patient Monitoring, PureWick, Advanced Tissue Regeneration, biologic drug delivery and BD Rowa. Interventional grew fastest of the four segments. Connected Care lagged as Alaris infusion pump capital sales fell. BD also won U.S. launch clearance for new vascular and hernia products.
Management is steering toward faster innovation, commercial investment in growth platforms and BD Excellence productivity work, and plans to detail the strategy at its December 10 Investor Day. The U.S. Government partnership brings a $19 billion investment plan and conditional tariff relief. The tension is that fiscal 2027 growth is guided to low single digits, with about 200 bps of drag from Alaris capital, so growth platforms must offset a weaker pump cycle.
Slides & documents
Open the slide deck (PDF, 29 pages) ↗
Showing the first 6 of 29 pages.
SEC filing
Key numbers
- Q4 revenue · GAAP
- $5.3 billion
- Q4 diluted EPS · GAAP
- $2.52
- Q4 adjusted diluted EPS · non-GAAP
- $4.15
- FY26 cash from continuing operations · GAAP
- $3.6 billion
- FY26 free cash flow · non-GAAP
- $2.9 billion
increased 5.4% as reported, 5.6% FXN
up 110.0% from a year ago
up 27.3% from a year ago
increased 30.0%
increased 42.5%
| Segment or metric | Value | Change |
|---|---|---|
| Medical Essentials | $1.8B | up 5.9% reported, 5.9% FXN |
| Connected Care | $1.3B | up 1.6% reported, 2.1% FXN |
| BioPharma Systems | $748.0M | up 6.5% reported, 7.0% FXN |
| Interventional | $1.5B | up 7.6% reported, 7.6% FXN |
Where each number comes from
- Q4 revenue: “Q4 revenue of $5.3 billion increased 5.4% as reported, 5.6% FXN”
- Q4 diluted EPS: “Q4 GAAP and adjusted diluted EPS of $2.52 and $4.15, respectively”
- Q4 adjusted diluted EPS: “Q4 GAAP and adjusted diluted EPS of $2.52 and $4.15, respectively”
- FY26 cash from continuing operations: “FY26 cash from continuing operations increased 30.0% to $3.6 billion and free cash flow increased 42.5% to $2.9 billion”
- FY26 free cash flow: “FY26 cash from continuing operations increased 30.0% to $3.6 billion and free cash flow increased 42.5% to $2.9 billion”
- Medical Essentials: “Medical Essentials2 | $1,786 | $1,686 | 5.9% | 5.9%”
- Connected Care: “Connected Care2 | $1,269 | $1,250 | 1.6% | 2.1%”
- BioPharma Systems: “BioPharma Systems2 | $748 | $702 | 6.5% | 7.0%”
- Interventional: “Interventional2 | $1,472 | $1,367 | 7.6% | 7.6%”
Copied from the press release ↗ and other documents in the SEC filing ↗. A figure is published only if its sentence is in those documents.
XBRL figures for this quarter arrive with the 10-Q or 10-K; the numbers above are from the press release.
Outlook
| Metric | Period | Outlook |
|---|---|---|
| Adjusted diluted EPS | fiscal 2027 | $13.10 to $13.30 |
Key takeaways
U.S. government partnership anchors domestic manufacturing push
BD intends to invest $19 billion in the U.S. over several years, with $3 billion directed toward manufacturing expansion. The agreement also provides relief from future Section 232 tariffs on covered products, subject to final scope and BD meeting agreed milestones.
Interventional launches broaden BD's addressable markets
BD launched the Liverty TIPS Stent Graft in the U.S. in Q1 FY27, entering a $2B global venous market, and received 510(k) clearance for Phasix ST Parastomal Hernia Mesh. Revello covered stent iliac data from the AGILITY trial were positive.
Advanced Patient Monitoring is a standout growth engine
APM grew 17.3% FXN in Q4, led by HemoSphere Alta and Acumen IQ products. BD credits sales force investment and says HemoSphere Alta had strong uptake.
Alaris share gains coexist with a capital headwind
BD Alaris gained additional share in Q4, and Medication Management Solutions grew mid-single digits excluding Alaris. Even so, FY27 guidance carries about a 200 bps Alaris capital headwind, and Connected Care grew only 2.1% FXN.
BioPharma Systems rides GLP-1 demand in biologic delivery
BioPharma Systems grew 7.0% FXN, with double-digit growth in Biologics on continued GLP-1 strength and healthy utilization. A moderating vaccine headwind partly offset it, and BD says it is expanding its position in next-generation biologic drug delivery.
Charts
Fourth quarter worked out from the annual figure.
Data
| Q4 FY24 | $5.4B * |
| Q1 FY25 | $5.2B |
| Q2 FY25 | $4.5B |
| Q3 FY25 | $4.7B |
| Q4 FY25 | $8.3B * |
| Q1 FY26 | $5.3B |
| Q2 FY26 | $4.7B |
| Q3 FY26 | $5.0B |
Data
| Q1 FY25 | $1.04 |
| Q2 FY25 | $1.07 |
| Q3 FY25 | $2.00 |
| Q1 FY26 | $1.34 |
| Q2 FY26 | -$1.11 |
| Q3 FY26 | $1.37 |
Fourth-quarter EPS appears once the press release is read; filings report it only for the full year.
Data
| Q4 FY24 | 11.4% |
| Q1 FY25 | 8.8% |
| Q2 FY25 | 8.5% |
| Q3 FY25 | 15.6% |
| Q4 FY25 | 14.1% |
| Q1 FY26 | 10.5% |
| Q2 FY26 | 2.0% |
| Q3 FY26 | 13.3% |
Data
| Q1 FY25 | $588.0M |
| Q1 FY26 | $549.0M |
Operating cash flow minus capital expenditure, from cash flow statements.
Questions
What is BD's U.S. Government partnership?
BD intends to invest $19 billion in the U.S. over several years, including $3 billion for manufacturing expansion, to strengthen domestic supply chains for essential medical consumables. It also provides relief from future Section 232 tariffs on covered products, subject to final scope and milestones.
Which BD products drove growth this quarter?
Advanced Patient Monitoring grew 17.3% FXN, led by HemoSphere Alta and Acumen IQ. PureWick, Advanced Tissue Regeneration, biologic drug delivery and BD Rowa also grew at double-digit rates.
What new products did BD launch or win clearance for?
BD launched the Liverty TIPS Stent Graft in the U.S. in Q1 FY27 after an EU launch in Q3 FY26. It received 510(k) clearance for Phasix ST Parastomal Hernia Mesh, with a U.S. launch expected in 1H FY27.
How is BD positioned in GLP-1 and biologic drug delivery?
BioPharma Systems grew 7.0% FXN, with double-digit growth in Biologics on continued GLP-1 strength. Management says it is expanding its position in next-generation biologic drug delivery.
What does BD expect for fiscal 2027?
BD guides to low single-digit FXN revenue growth, including about a 200 bps Alaris capital headwind, and adjusted EPS of $13.10 to $13.30. Q1 revenue growth is expected at the low end of the range, and BD will hold an Investor Day on December 10.
Call recording
Call recording on YouTube ↗. Official replay ↗.





